| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
56,200,000 |
| Market
Cap: |
110.15(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.5 - $7.84 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 10.2 |
| Insider 6 Months : 10.2 |
| Insider 3/6 Months : 20.5 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Syros Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cancer and diseases resulting from mutations of a single gene, also known as monogenic diseases, and building a clinical stage pipeline of gene control medicines. Co.'s primary product candidates are: Tamibarotene, which is a selective retinoic acid receptor alpha agonist that is being evaluated in combination with azacitidine; SY-2101, which is an oral form of arsenic trioxide; and SY-5609, which is a selective oral inhibitor of cyclin-dependent kinase 7 that is being evaluated in combination with chemotherapy in relapsed/refractory metastatic pancreatic cancer patients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
200,000 |
200,000 |
1,104,977 |
1,121,909 |
| Total Buy Value |
$321,920 |
$321,920 |
$4,321,918 |
$4,427,874 |
| Total People Bought |
2 |
2 |
3 |
4 |
| Total Buy Transactions |
5 |
5 |
6 |
8 |
| Total Shares Sold |
34,837 |
45,438 |
58,012 |
66,049 |
| Total Sell Value |
$178,365 |
$230,844 |
$286,799 |
$318,236 |
| Total People Sold |
1 |
2 |
2 |
3 |
| Total Sell Transactions |
1 |
3 |
5 |
7 |
| End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Roth David |
Chief Medical Officer |
• – – |
2024-04-03 |
4 |
AS |
$4.95 |
$51,732 |
D/D |
(10,451) |
0 |
|
-68% |
|
| Roth David |
Chief Medical Officer |
• – – |
2024-04-02 |
4 |
AS |
$4.98 |
$747 |
D/D |
(150) |
10,451 |
|
-59% |
|
| Simonian Nancy A |
|
– • – |
2024-04-01 |
4 |
D |
$5.12 |
$71,946 |
D/D |
(14,052) |
131,658 |
|
- |
|
| Haas Jason |
Chief Financial Officer |
• – – |
2024-04-01 |
4 |
D |
$5.12 |
$24,228 |
D/D |
(4,732) |
24,552 |
|
- |
|
| Chee Conley |
President & CEO |
• • – |
2024-04-01 |
4 |
D |
$5.12 |
$17,920 |
D/D |
(3,500) |
22,504 |
|
- |
|
| Stephens Kristin |
Chief Development Officer |
• – – |
2024-04-01 |
4 |
D |
$5.12 |
$21,596 |
D/D |
(4,218) |
25,237 |
|
- |
|
| Roth David |
Chief Medical Officer |
• – – |
2024-04-01 |
4 |
D |
$5.12 |
$24,228 |
D/D |
(4,732) |
10,601 |
|
- |
|
| Simonian Nancy A |
|
– • – |
2024-03-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
45,566 |
145,710 |
|
- |
|
| Haas Jason |
Chief Financial Officer |
• – – |
2024-03-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,333 |
29,284 |
|
- |
|
| Chee Conley |
President & CEO |
• • – |
2024-03-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,666 |
26,004 |
|
- |
|
| Stephens Kristin |
Chief Development Officer |
• – – |
2024-03-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,666 |
29,455 |
|
- |
|
| Roth David |
Chief Medical Officer |
• – – |
2024-03-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,333 |
15,333 |
|
- |
|
| Quirk Gerald E |
Chief Legal & Compliance Offic |
• – – |
2024-03-28 |
4 |
D |
$5.59 |
$39,387 |
D/D |
(7,046) |
39,757 |
|
- |
|
| Quirk Gerald E |
Chief Legal & Compliance Offic |
• – – |
2024-03-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
22,500 |
46,803 |
|
- |
|
| Akkaraju Srinivas |
Director |
– • – |
2023-12-21 |
4 |
B |
$4.42 |
$3,999,998 |
I/I |
904,977 |
1,786,427 |
2.1 |
-11% |
|
| Roth David |
Chief Medical Officer |
• – – |
2023-12-12 |
4 |
AS |
$4.95 |
$31,121 |
D/D |
(6,287) |
0 |
|
3% |
|
| Roth David |
Chief Medical Officer |
• – – |
2023-12-06 |
4 |
AS |
$3.95 |
$24,834 |
D/D |
(6,287) |
6,287 |
|
17% |
|
| Simonian Nancy A |
President & CEO |
• • – |
2023-11-01 |
4 |
D |
$2.22 |
$29,750 |
D/D |
(13,401) |
100,144 |
|
- |
|
| Chee Conley |
Chief Commercial Officer |
• – – |
2023-11-01 |
4 |
D |
$2.22 |
$13,329 |
D/D |
(6,004) |
12,338 |
|
- |
|
| Stephens Kristin |
Chief Development Officer |
• – – |
2023-11-01 |
4 |
D |
$2.22 |
$12,601 |
D/D |
(5,676) |
15,789 |
|
- |
|
| Haas Jason |
Chief Financial Officer |
• – – |
2023-11-01 |
4 |
D |
$2.22 |
$13,988 |
D/D |
(6,301) |
13,951 |
|
- |
|
| Roth David |
Chief Medical Officer |
• – – |
2023-11-01 |
4 |
D |
$2.22 |
$13,988 |
D/D |
(6,301) |
12,574 |
|
- |
|
| Simonian Nancy A |
President & CEO |
• • – |
2023-10-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
40,125 |
113,545 |
|
- |
|
| Chee Conley |
Chief Commercial Officer |
• – – |
2023-10-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
17,000 |
18,342 |
|
- |
|
| Stephens Kristin |
Chief Development Officer |
• – – |
2023-10-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
17,000 |
21,465 |
|
- |
|
157 Records found
|
|
Page 1 of 7 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.04 (2.08%) 
